Related references
Note: Only part of the references are listed.Comparing Charlson and Elixhauser comorbidity indices with different weightings to predict in-hospital mortality: an analysis of national inpatient data
Narayan Sharma et al.
BMC HEALTH SERVICES RESEARCH (2021)
Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study
Pete T. Kinnunen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
Ang Li et al.
THROMBOSIS RESEARCH (2019)
Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion
Yi Yang et al.
CANCER RESEARCH (2019)
Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer
P. T. T. Kinnunen et al.
CANCER CAUSES & CONTROL (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study
Margaret C. Fang et al.
MEDICAL CARE (2017)
Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data The AHRQ Elixhauser Comorbidity Index
Brian J. Moore et al.
MEDICAL CARE (2017)
Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years
Gry S. Haaland et al.
JAMA INTERNAL MEDICINE (2017)
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
Chiara Melloni et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
Pete T. T. Kinnunen et al.
BMC CANCER (2017)
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis
Amanda Kirane et al.
CANCER RESEARCH (2015)
Epidemiology of venous thromboembolism
John A. Heit
NATURE REVIEWS CARDIOLOGY (2015)
Thrombin Drives Tumorigenesis in Colitis-Associated Colon Cancer
Brian Turpin et al.
CANCER RESEARCH (2014)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Comparison of different comorbidity measures for use with administrative data in predicting short- and long-term mortality
Yu-Tseng Chu et al.
BMC HEALTH SERVICES RESEARCH (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States
Richard H. White et al.
THROMBOSIS RESEARCH (2010)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism
S Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)